Macogenic G2 for extracorporeal photopheresis



Extracorporeal Photopheresis (ECP) has been recognised by the scientific community as a therapeutic option to treat various disorders, such as:

. Cutaneous T-cell lymphoma (Sezary syndrome)

. GVHD (acute and chronic)

. Solid organ transplant rejection

Macopharma has developed a complete product range for the off-line extracorporeal photpheresis technique.




Extracorporeal photopheresis (ECP) is based on the exposure of peripheral blood mononuclear cells to the photosensitizing agent (8-methoxypsoralen or 8-MOP) and UVA irradiation.
Mononuclear cells are harvested by an apheresis device usually and reinfused to the patient after cell irradiation.

Ref. XUV8501Q – Bag for U.V. treatment of blood cellsXUV8501Q

Download brochure for product description

Ref. CSL1800XA – Methoxsalen (8-MOP) MACO PHARMA 20 micrograms/mL, solution

Produit Thérapeutique Annexe (PTA)
Marketing Authorisation in France
AMM PTA N°: TA 07.10.109CSL1800XA

  • Volume: 5 mL

Download brochure for product description

Ref. 9MG2000 – Macogenic G2 9MG2000

  • Weight: 67 kg
  • Dimensions: 87 cm (width) x 64 cm (depth) x 38 cm (height)

Download brochure for product description